|
male |
32 |
|
humans |
30 |
|
adult |
24 |
|
female |
24 |
|
middle aged |
23 |
|
adolescent |
16 |
|
aged |
16 |
|
retrospective studies |
14 |
|
rhizopus microsporus |
13 |
|
species index: fungi |
13 |
|
treatment outcome |
12 |
|
bone marrow transplantation |
11 |
|
transplantation, homologous |
11 |
|
alemtuzumab |
10 |
|
biopsy |
10 |
|
child |
10 |
|
medical sciences |
10 |
|
aged, 80 and over |
9 |
|
aml |
8 |
|
animal cell |
8 |
|
animals |
8 |
|
cytomegalovirus |
8 |
|
dna, viral - analysis |
8 |
|
graft versus host disease |
8 |
|
hematology |
8 |
|
hematopoiesis |
8 |
|
hematopoietic stem cell transplantation |
8 |
|
hematopoietic stem cell transplantation - adverse effects |
8 |
|
polymerase chain reaction |
8 |
|
prevalence |
8 |
|
prognosis |
8 |
|
prospective studies |
8 |
|
recurrence |
8 |
|
viral load |
8 |
|
virus activation |
8 |
|
young adult |
8 |
|
antibiotic prophylaxis |
7 |
|
antibodies, monoclonal, murine-derived |
7 |
|
child, preschool |
7 |
|
chinese |
7 |
|
dna, viral - blood |
7 |
|
follow-up studies |
7 |
|
haematopoietic stem cell transplantation |
7 |
|
hematopoietic stem cell transplantation - adverse effects - methods |
7 |
|
hepatitis b surface antigens - blood |
7 |
|
immunophenotyping |
7 |
|
neoplasm staging |
7 |
|
prophylaxis |
7 |
|
reverse transcriptase polymerase chain reaction |
7 |
|
urine - virology |
7 |
|
acute myeloid leukemia |
6 |
|
allele |
6 |
|
antineoplastic agents - administration and dosage - adverse effects |
6 |
|
asian continental ancestry group |
6 |
|
benzenesulfonates - administration and dosage - adverse effects |
6 |
|
bk virus - isolation & purification - physiology |
6 |
|
bone density |
6 |
|
bone marrow transplantation - adverse effects |
6 |
|
breakthrough invasive fungal infections |
6 |
|
bronchiolitis obliterans syndrome |
6 |
|
candida tropicalis fungaemia |
6 |
|
china |
6 |
|
drug resistance, neoplasm - drug effects - genetics |
6 |
|
echinocandin |
6 |
|
fluorodeoxyglucose f18 - diagnostic use |
6 |
|
gene expression regulation, leukemic |
6 |
|
graft vs host disease - drug therapy - etiology - pathology |
6 |
|
haematological malignancies |
6 |
|
hepatitis b surface antigens - immunology |
6 |
|
leukemia - therapy |
6 |
|
leukemia, myeloid, acute - drug therapy - enzymology - genetics - pathology |
6 |
|
lung function decline |
6 |
|
messenger rna |
6 |
|
multiple myeloma - therapy |
6 |
|
nk-cell lymphoma |
6 |
|
risk factors |
6 |
|
rituximab |
6 |
|
sorafenib |
6 |
|
stem cell transplantation - adverse effects |
6 |
|
tissue donors |
6 |
|
tomography, x-ray computed |
6 |
|
transcription factor gata 2 |
6 |
|
zebrafish |
6 |
|
aldehyde dehydrogenase - analysis |
5 |
|
animals, genetically modified |
5 |
|
animals, newborn |
5 |
|
anti-bacterial agents - pharmacology - therapeutic use |
5 |
|
antibodies, monoclonal - administration & dosage |
5 |
|
antibodies, monoclonal, humanized |
5 |
|
antifungal drug |
5 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - adverse effects - therapeutic use |
5 |
|
asia |
5 |
|
azacitidine |
5 |
|
bk virus - isolation & purification |
5 |
|
ciprofloxacin - pharmacology - therapeutic use |
5 |
|
dexamethasone - administration & dosage - adverse effects |
5 |
|
disease-free survival |
5 |
|
dli |
5 |
|
fatal outcome |
5 |
|
flt3-itd |
5 |
|
fludarabine |
5 |
|
fnd |
5 |
|
graft vs host disease - epidemiology |
5 |
|
graft vs host disease - immunology |
5 |
|
hematologic neoplasms - complications - therapy |
5 |
|
hematopoietic stem cell transplantation - methods |
5 |
|
hematopoietic stem cells |
5 |
|
hodgkin lymphoma |
5 |
|
homing |
5 |
|
hong kong - epidemiology |
5 |
|
hsct |
5 |
|
idiopathic thrombocytopenic purpura |
5 |
|
incidence |
5 |
|
indolent lymphoma |
5 |
|
killer cells, natural |
5 |
|
leukaemia |
5 |
|
leukemia, large granular lymphocytic - complications - drug therapy |
5 |
|
leukemia, myeloid - diagnosis - pathology |
5 |
|
leukemia, prolymphocytic, t-cell - drug therapy - ethnology |
5 |
|
liver diseases - drug therapy - etiology |
5 |
|
liver gvhd |
5 |
|
low‐dose |
5 |
|
lymphocyte transfusion - adverse effects |
5 |
|
lymphoma - therapy |
5 |
|
lymphoma, b-cell - drug therapy - ethnology |
5 |
|
lymphoma, non-hodgkin - drug therapy - ethnology |
5 |
|
lymphoma, t-cell - epidemiology - pathology - therapy |
5 |
|
mature t-cell lymphoma |
5 |
|
mitoxantrone - administration & dosage - adverse effects |
5 |
|
mucosa-associated lymphoid tissue |
5 |
|
neoplasm transplantation |
5 |
|
neoplastic stem cells - pathology |
5 |
|
nivolumab |
5 |
|
non-gastric marginal zone lymphoma |
5 |
|
pembrolizumab |
5 |
|
pet/ct |
5 |
|
polycythemia vera |
5 |
|
polyoma bk virus |
5 |
|
polyomavirus infections - prevention & control - virology |
5 |
|
positron-emission tomography |
5 |
|
post-transplant lymphoproliferative disorders |
5 |
|
precursor cell lymphoblastic leukemia-lymphoma - pathology |
5 |
|
protein-losing enteropathies - drug therapy - etiology |
5 |
|
refractory |
5 |
|
relapse |
5 |
|
remission induction |
5 |
|
sex factors |
5 |
|
splenic marginal zone lymphoma |
5 |
|
survival analysis |
5 |
|
transplantation, homologous - adverse effects |
5 |
|
tumor virus infections - prevention & control - virology |
5 |
|
vidarabine - administration & dosage - adverse effects - analogs & derivatives |
5 |
|
virus replication - drug effects |
5 |
|
acute disease |
4 |
|
acute leukemia |
4 |
|
acute myeloid leukemic |
4 |
|
acute promyelocytic leukemia |
4 |
|
adenoviridae - genetics - isolation & purification |
4 |
|
adenoviridae - isolation & purification |
4 |
|
adenoviridae - physiology |
4 |
|
adenoviridae infections - etiology - pathology |
4 |
|
adoptive transfer |
4 |
|
alanine transaminase - blood |
4 |
|
alkaline phosphatase - blood |
4 |
|
antibodies, antinuclear - analysis |
4 |
|
antibodies, monoclonal - administration & dosage - adverse effects |
4 |
|
antibodies, neoplasm - administration & dosage - adverse effects |
4 |
|
antigens, cd20 - metabolism |
4 |
|
antigens, viral - blood |
4 |
|
antineoplastic agents - administration & dosage - adverse effects |
4 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
|
antinuclear antibody |
4 |
|
antiviral agents - therapeutic use |
4 |
|
arsenic trioxide |
4 |
|
aspartate aminotransferases - blood |
4 |
|
autoimmune diseases - blood - complications - drug therapy - virology |
4 |
|
bilirubin - blood |
4 |
|
biological markers - metabolism |
4 |
|
bk virus - genetics - isolation & purification |
4 |
|
bk virus - physiology |
4 |
|
bleomycin |
4 |
|
bone marrow - drug effects - pathology - radionuclide imaging |
4 |
|
bone marrow transplantation - adverse effects - methods - pathology |
4 |
|
busulfan - adverse effects - therapeutic use |
4 |
|
cancer prognosis |
4 |
|
cancer recurrence |
4 |
|
cancer regression |
4 |
|
cancer risk |
4 |
|
cancer staging |
4 |
|
carrier state - epidemiology - immunology - microbiology |
4 |
|
cell proliferation |
4 |
|
china - epidemiology |
4 |
|
chinese patients |
4 |
|
chronic disease |
4 |
|
cisplatin |
4 |
|
clinical observations |
4 |
|
clofarabine |
4 |
|
cohort studies |
4 |
|
computer systems |
4 |
|
corticosteroid |
4 |
|
cyclophosphamide |
4 |
|
cyclosporin |
4 |
|
cystitis - diagnosis - etiology - virology |
4 |
|
cystitis - etiology - pathology - urine - virology |
4 |
|
cytarabine |
4 |
|
cytomegalovirus infections - blood - chemically induced - prevention & control |
4 |
|
cytomegalovirus reactivation |
4 |
|
dexamethasone |
4 |
|
diffusion-weighted imaging |
4 |
|
disease progression |
4 |
|
dna primers |
4 |
|
dna, viral - analysis - blood - urine |
4 |
|
dwi |
4 |
|
embryo, mammalian - physiology |
4 |
|
embryo, nonmammalian |
4 |
|
embryo, nonmammalian - cytology - metabolism |
4 |
|
embryo, nonmammalian - metabolism |
4 |
|
epstein barr virus |
4 |
|
epstein-barr virus dna |
4 |
|
epstein-barr virus infections - complications - drug therapy - pathology |
4 |
|
extramedullary |
4 |
|
fdg pet/ct |
4 |
|
fdg-avid lymphoma |
4 |
|
fever - etiology |
4 |
|
flt3/internal tandem duplication |
4 |
|
fluorescent antibody technique, indirect |
4 |
|
gene expression regulation, developmental |
4 |
|
gene expression regulation, developmental - drug effects |
4 |
|
gene frequency |
4 |
|
glucocorticoids - therapeutic use |
4 |
|
graft survival |
4 |
|
graft vs host disease - epidemiology - etiology - microbiology |
4 |
|
graft-versus-host disease |
4 |
|
green fluorescent proteins - metabolism |
4 |
|
gut toxicity |
4 |
|
haemorrhagic cystitis |
4 |
|
helicobacter infections - immunology |
4 |
|
helicobacter pylori |
4 |
|
hematopoiesis - drug effects - genetics - physiology |
4 |
|
hematopoiesis, extramedullary - physiology |
4 |
|
hematopoietic stem cells - cytology - metabolism |
4 |
|
hematopoietic stem cells - cytology - physiology |
4 |
|
hematuria - diagnosis - etiology - virology |
4 |
|
hemorrhage - etiology - pathology - surgery - virology |
4 |
|
hepatitis - drug therapy - etiology - pathology |
4 |
|
hepatitis b - complications - drug therapy - virology |
4 |
|
hepatitis b - drug therapy - etiology - pathology |
4 |
|
hepatitis b - epidemiology |
4 |
|
hepatitis b - mortality - therapy - virology |
4 |
|
hepatitis b antibodies - blood |
4 |
|
hepatitis b surface antigens - metabolism |
4 |
|
hepatitis b virus - genetics - immunology |
4 |
|
hepatitis b virus - growth & development |
4 |
|
hepatitis b virus - physiology |
4 |
|
hepatitis b, chronic - drug therapy - immunology |
4 |
|
hepatitis b, chronic - etiology - immunology - transmission |
4 |
|
herpes zoster |
4 |
|
herpes zoster - epidemiology - etiology - pathology |
4 |
|
herpesvirus 4, human - isolation & purification - physiology |
4 |
|
histocompatibility |
4 |
|
histocompatibility testing - methods |
4 |
|
hla antigens - genetics |
4 |
|
hla typing |
4 |
|
hodgkin disease - drug therapy - pathology - virology |
4 |
|
icm |
4 |
|
ileal neoplasms - drug therapy - pathology - radionuclide imaging |
4 |
|
immunocompromised host - drug effects |
4 |
|
immunoenzyme techniques |
4 |
|
immunosuppression - adverse effects |
4 |
|
immunosuppressive agents - administration and dosage |
4 |
|
immunosuppressive agents - adverse effects - therapeutic use |
4 |
|
immunosuppressive agents - therapeutic use |
4 |
|
in situ hybridization |
4 |
|
infant |
4 |
|
inhibitor of apoptosis proteins - genetics |
4 |
|
interventions |
4 |
|
jak2 |
4 |
|
kidney - cytology - metabolism |
4 |
|
kidney neoplasms - pathology |
4 |
|
kidney transplantation |
4 |
|
kidneys |
4 |
|
killer cells, natural - metabolism |
4 |
|
lamivudine - therapeutic use |
4 |
|
leukemia stem cells |
4 |
|
liver - pathology |
4 |
|
liver diseases - drug therapy - etiology - pathology |
4 |
|
liver diseases - etiology - pathology |
4 |
|
liver failure, acute - epidemiology - etiology |
4 |
|
living donors |
4 |
|
longitudinal studies |
4 |
|
lymphoma - blood - complications - drug therapy - virology |
4 |
|
lymphoma - pathology |
4 |
|
lymphoma, b-cell - metabolism - pathology - radionuclide imaging |
4 |
|
lymphoma, large b-cell, diffuse - drug therapy - pathology - virology |
4 |
|
lymphoma, t-cell - immunology - pathology - radionuclide imaging |
4 |
|
lymphoma, t-cell - metabolism - pathology - radionuclide imaging |
4 |
|
medicine & public health |
4 |
|
methotrexate |
4 |
|
microenvironment |
4 |
|
monitoring, physiologic - methods |
4 |
|
monoclonal antibodies |
4 |
|
myeloid sarcoma |
4 |
|
myeloproliferative disease |
4 |
|
natural killer t-cells - immunology - pathology |
4 |
|
neoplasms, multiple primary |
4 |
|
neovascularization, physiologic - genetics |
4 |
|
nk/t-cell lymphoma |
4 |
|
nod/scid mice |
4 |
|
non-hodgkin lymphoma |
4 |
|
nose neoplasms - immunology - pathology - radionuclide imaging |
4 |
|
oncology |
4 |
|
pancytopenia - blood - complications - drug therapy - virology |
4 |
|
papillomavirus infections - diagnosis - etiology - virology |
4 |
|
papillomavirus infections - etiology - pathology |
4 |
|
pcna |
4 |
|
platelet count |
4 |
|
polymerase chain reaction - methods |
4 |
|
polyomavirus infections - blood - urine - virology |
4 |
|
polyomavirus infections - complications - diagnosis |
4 |
|
positron-emission tomography and computed tomography |
4 |
|
positron-emission tomography and computed tomography - methods |
4 |
|
postoperative complications - blood - urine - virology |
4 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy - etiology |
4 |
|
prednisolone |
4 |
|
prednisolone - therapeutic use |
4 |
|
proliferating cell nuclear antigen - genetics - metabolism |
4 |
|
proportional hazards models |
4 |
|
proteinuria - etiology |
4 |
|
purpura, thrombocytopenic - ethnology - immunology - physiopathology - therapy |
4 |
|
purpura, thrombocytopenic, idiopathic - drug therapy - genetics - immunology |
4 |
|
quantitative pcr |
4 |
|
radiopharmaceuticals - diagnostic use |
4 |
|
renal transplantation |
4 |
|
reverse transcriptase inhibitors - therapeutic use |
4 |
|
reverse transcriptase polymerase chain reaction - methods |
4 |
|
rna, messenger - metabolism |
4 |
|
sarcoma, myeloid - drug therapy - pathology - radionuclide imaging |
4 |
|
sarcoma, myeloid - pathology - radionuclide imaging |
4 |
|
sensitivity and specificity |
4 |
|
sheep - embryology |
4 |
|
smile |
4 |
|
splenectomy |
4 |
|
stem cell transplantation |
4 |
|
stem cell transplantation - adverse effects - methods |
4 |
|
stem cells - chemistry - physiology |
4 |
|
steroids |
4 |
|
steroids - therapeutic use |
4 |
|
survival rate |
4 |
|
suv max |
4 |
|
therapeutic irrigation - methods |
4 |
|
therapeutic trials |
4 |
|
transplantation chimera |
4 |
|
transplantation conditioning - adverse effects - methods |
4 |
|
transplantation, autologous |
4 |
|
tretinoin - pharmacology |
4 |
|
tumor virus infections - blood - urine - virology |
4 |
|
tumor virus infections - etiology - pathology |
4 |
|
urinary bladder - metabolism - pathology |
4 |
|
urinary tract infections - diagnosis - urine - virology |
4 |
|
valganciclovir |
4 |
|
varicella-zoster virus |
4 |
|
vascular endothelial growth factor a - genetics |
4 |
|
vascular neoplasms - pathology |
4 |
|
vincristine |
4 |
|
viremia - virology |
4 |
|
virus activation - drug effects |
4 |
|
whole-body mri |
4 |
|
zebrafish - embryology - genetics - physiology |
4 |
|
3d osteogenic niche |
3 |
|
acute myeloid leukaemia |
3 |
|
acute myeloid leukemia (aml) |
3 |
|
adenine nucleotides - administration & dosage - adverse effects |
3 |
|
adenoviruses, human - isolation & purification |
3 |
|
aldehyde dehydrogenase |
3 |
|
aldehyde dehydrogenase - antagonists & inhibitors - physiology |
3 |
|
alleles |
3 |
|
amino acid substitution |
3 |
|
aminopeptidases - genetics - metabolism - physiology |
3 |
|
analgesics - adverse effects - therapeutic use |
3 |
|
angiogenesis inhibitors - pharmacology |
3 |
|
animal experiment |
3 |
|
animal model |
3 |
|
animal tissue |
3 |
|
anti-infective agents - therapeutic use |
3 |
|
antibodies, monoclonal |
3 |
|
antibodies, monoclonal - therapeutic use |
3 |
|
antibodies, neoplasm - administration & dosage |
3 |
|
antibodies, neoplasm - therapeutic use |
3 |
|
anticonvulsants - adverse effects - therapeutic use |
3 |
|
antigens, cd34 - analysis |
3 |
|
antigens, neoplasm - analysis |
3 |
|
antimetabolites, antineoplastic - administration & dosage - adverse effects |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
3 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
3 |
|
apoptosis |
3 |
|
apoptosis - drug effects |
3 |
|
apoptosis regulatory proteins |
3 |
|
arabinonucleosides - administration & dosage - adverse effects |
3 |
|
aryl hydrocarbon hydroxylases |
3 |
|
asian continental ancestry group - genetics |
3 |
|
bk virus |
3 |
|
bk virus - genetics - isolation & purification - physiology |
3 |
|
bkv |
3 |
|
blood transfusion, autologous |
3 |
|
bmt |
3 |
|
bmt recipients |
3 |
|
bone marrow |
3 |
|
bone marrow cells - physiology |
3 |
|
bone marrow transplantation - immunology |
3 |
|
bone marrow transplantation - immunology - methods - mortality |
3 |
|
bone marrow transplantation - methods |
3 |
|
bronchoalveolar lavage fluid - virology |
3 |
|
cancer microenvironment |
3 |
|
carmustine - administration & dosage |
3 |
|
carrier state - virology |
3 |
|
caspase 3 |
3 |
|
caspases |
3 |
|
caspases - drug effects - metabolism |
3 |
|
catheters, indwelling - adverse effects |
3 |
|
cell count |
3 |
|
cell differentiation - drug effects |
3 |
|
cell division |
3 |
|
cell lineage |
3 |
|
cell proliferation - drug effects |
3 |
|
central venous catheter |
3 |
|
chickenpox vaccine - administration & dosage |
3 |
|
ciprofloxacin - therapeutic use |
3 |
|
cml |
3 |
|
combined modality therapy |
3 |
|
communicable diseases |
3 |
|
cystitis - etiology - prevention & control - virology |
3 |
|
cystitis - etiology - urine |
3 |
|
cytarabine - administration & dosage |
3 |
|
cytarabine - administration & dosage - adverse effects |
3 |
|
cytochrome p-450 enzyme system - genetics |
3 |
|
cytomegalovirus - drug effects |
3 |
|
cytotoxic t-lymphocytes precursor frequency |
3 |
|
dexamethasone - administration & dosage |
3 |
|
diphenhydramine - therapeutic use |
3 |
|
disease models, animal |
3 |
|
dna - analysis |
3 |
|
dna chimerism |
3 |
|
drug evaluation |
3 |
|
embryo, nonmammalian - physiology |
3 |
|
embryonic development |
3 |
|
endothelium, vascular - injuries |
3 |
|
engraftment |
3 |
|
enzyme activation |
3 |
|
enzyme inhibitors - pharmacology |
3 |
|
epigenetic modifiers |
3 |
|
erythroid precursor cells - metabolism |
3 |
|
erythropoiesis - drug effects - physiology |
3 |
|
essential thrombocythemia |
3 |
|
etoposide - administration & dosage |
3 |
|
exons |
3 |
|
familial hypercholesterolemia |
3 |
|
feces - virology |
3 |
|
fibroblast growth factor 1 - administration & dosage |
3 |
|
flow cytometry - methods |
3 |
|
flt3 |
3 |
|
frequency |
3 |
|
fusion proteins, bcr-abl |
3 |
|
gamma-aminobutyric acid - adverse effects - analogs & derivatives - therapeutic use |
3 |
|
ganciclovir - administration & dosage - analogs & derivatives |
3 |
|
gastrointestinal tract - chemistry - virology |
3 |
|
gene expression profiling |
3 |
|
gene expression profiling - methods |
3 |
|
gene expression regulation - drug effects - genetics |
3 |
|
gene mutations |
3 |
|
gene targeting - methods |
3 |
|
genotype |
3 |
|
glycoproteins - administration & dosage |
3 |
|
glycoproteins - genetics - physiology |
3 |
|
glycoproteins - metabolism |
3 |
|
graft vs tumor effect |
3 |
|
granulocyte precursor cells - physiology |
3 |
|
green fluorescent proteins - genetics |
3 |
|
helper t-cell precursor frequency |
3 |
|
hematologic neoplasms - mortality - therapy |
3 |
|
hematopoiesis - drug effects |
3 |
|
hematopoietic stem cell transplantation - utilization |
3 |
|
hematopoietic stem cells - cytology |
3 |
|
hematopoietic stem cells - cytology - enzymology |
3 |
|
hematopoietic stem cells - drug effects - physiology |
3 |
|
hematopoietic system |
3 |
|
hemoglobins - biosynthesis - drug effects |
3 |
|
herpes zoster - prevention & control |
3 |
|
histamine h1 antagonists - therapeutic use |
3 |
|
histocompatibility - immunology |
3 |
|
histocompatibility testing |
3 |
|
hla-identical siblings |
3 |
|
ifn-γ-producing cell frequency |
3 |
|
ileal diseases - etiology |
3 |
|
ileal neoplasms - complications - diagnosis - pathology - radiotherapy - surgery |
3 |
|
immunocompetence |
3 |
|
immunocompromised host |
3 |
|
immunosuppressive agents |
3 |
|
immunotherapy |
3 |
|
in situ hybridization, fluorescence |
3 |
|
intensive chemotherapy |
3 |
|
intercellular signaling peptides and proteins - administration & dosage |
3 |
|
intercellular signaling peptides and proteins - metabolism |
3 |
|
internal tandem duplication of fms‐like tyrosine kinase 3 (flt3‐itd) |
3 |
|
intestinal obstruction - etiology |
3 |
|
janus kinase 2 - antagonists and inhibitors - genetics - metabolism |
3 |
|
janus kinase 2 - genetics - physiology |
3 |
|
karyotyping |
3 |
|
kit |
3 |
|
leukemia |
3 |
|
leukemia, large granular lymphocytic - diagnosis - drug therapy - epidemiology |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics - therapy |
3 |
|
leukemia, myeloid, acute - blood - pathology |
3 |
|
leukemia, myeloid, acute - drug therapy |
3 |
|
leukemia, myeloid, acute - drug therapy - prevention & control |
3 |
|
leukemia, t-cell - drug therapy |
3 |
|
limiting dilution assay |
3 |
|
lipid metabolism |
3 |
|
low-density lipoprotein |
3 |
|
lymphocyte transfusion |
3 |
|
lymphoma relapses post-hsct |
3 |
|
lymphoma, follicular - complications - diagnosis - pathology - radiotherapy - surgery |
3 |
|
lymphoma, large b-cell, diffuse - drug therapy |
3 |
|
lymphoproliferative disorders - complications - drug therapy |
3 |
|
mechanical force |
3 |
|
medical oncology - methods |
3 |
|
melphalan - administration & dosage |
3 |
|
meningeal neoplasms - drug therapy |
3 |
|
metalloendopeptidases - genetics - physiology |
3 |
|
mice |
3 |
|
mice, scid |
3 |
|
microtubule-associated proteins - physiology |
3 |
|
minimal residual disease |
3 |
|
mitoxantrone - administration & dosage |
3 |
|
morpholines - administration & dosage |
3 |
|
mutation |
3 |
|
mycobacterium tuberculosis - pathogenicity |
3 |
|
myeloablative agonists - therapeutic use |
3 |
|
myelodysplastic syndrome |
3 |
|
myelofibrosis |
3 |
|
nasopharyngeal neoplasms - surgery |
3 |
|
necrotic cell death |
3 |
|
neovascularization, physiologic |
3 |
|
neutropenia |
3 |
|
neutropenia - epidemiology |
3 |
|
neutrophils |
3 |
|
npm1 |
3 |
|
nuclear family |
3 |
|
oligonucleotide array sequence analysis |
3 |
|
oligonucleotides, antisense - administration & dosage |
3 |
|
omacetaxine mepesuccinate |
3 |
|
optical trap |
3 |
|
peripheral blood |
3 |
|
personalized drug screening |
3 |
|
ph-negative leukaemia |
3 |
|
philadelphia chromosome |
3 |
|
phospholipase c gamma - drug effects - genetics - physiology |
3 |
|
phosphorylation |
3 |
|
platelet-derived growth factor - administration & dosage |
3 |
|
polycythemia vera - enzymology - genetics - pathology |
3 |
|
polymorphism, genetic |
3 |
|
polyomavirus infections - drug therapy - etiology |
3 |
|
polyomavirus infections - drug therapy - virology |
3 |
|
polyomavirus infections - etiology |
3 |
|
polyomavirus infections - immunology - urine - virology |
3 |
|
poor engraftment |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics |
3 |
|
predictive value of tests |
3 |
|
premedication |
3 |
|
primary follicular lymphoma |
3 |
|
prognostication |
3 |
|
protein-tyrosine kinases - antagonists and inhibitors - genetics - metabolism |
3 |
|
pure red cell aplasia |
3 |
|
radiotherapy, adjuvant |
3 |
|
reactivation |
3 |
|
receptors, tumor necrosis factor - administration & dosage - genetics - metabolism |
3 |
|
regeneration |
3 |
|
respiratory system - virology |
3 |
|
rheumatoid arthritis |
3 |
|
rna, messenger - genetics - metabolism |
3 |
|
safety |
3 |
|
siblings |
3 |
|
signal transduction |
3 |
|
small intestine |
3 |
|
splenomegaly |
3 |
|
stat5 transcription factor - metabolism |
3 |
|
statin therapy |
3 |
|
steroid 16-alpha-hydroxylase |
3 |
|
steroid hydroxylases - genetics |
3 |
|
stromal cells - cytology |
3 |
|
t-cell large granular lymphocyte leukemia |
3 |
|
t-lymphocytes, cytotoxic - immunology |
3 |
|
t-lymphocytes, helper-inducer - immunology |
3 |
|
target therapy |
3 |
|
targeted treatment |
3 |
|
thrombocytopenia - complications - therapy |
3 |
|
thrombocytopenia - epidemiology |
3 |
|
time factors |
3 |
|
transplant related mortality |
3 |
|
transplantation chimera - genetics |
3 |
|
transplantation conditioning |
3 |
|
transplantation, autologous - utilization |
3 |
|
transplantation, heterologous |
3 |
|
trismus - chemically induced |
3 |
|
tuberculosis |
3 |
|
tuberculosis - epidemiology - microbiology - mortality |
3 |
|
tumor virus infections - drug therapy - etiology |
3 |
|
tumor virus infections - drug therapy - virology |
3 |
|
tumor virus infections - immunology - urine - virology |
3 |
|
ubiquitin-protein ligases |
3 |
|
up-regulation - drug effects - genetics |
3 |
|
vascular endothelial growth factor a - administration & dosage |
3 |
|
venous thrombosis |
3 |
|
venous thrombosis - etiology |
3 |
|
vidarabine - administration & dosage - analogs & derivatives |
3 |
|
virus latency |
3 |
|
virus shedding |
3 |
|
warfarin - adverse effects |
3 |
|
zebrafish - embryology |
3 |
|
zebrafish - embryology - genetics |
3 |
|
zebrafish - embryology - genetics - metabolism |
3 |
|
zebrafish proteins - antagonists and inhibitors - genetics - metabolism |
3 |
|
zebrafish proteins - genetics - metabolism |
3 |
|
zebrafish proteins - physiology |
3 |
|
acute gvhd |
2 |
|
allogeneic bmt |
2 |
|
allogeneic hematopoietic stem cell transplantation |
2 |
|
allogeneic stem cell transplantation |
2 |
|
amino acid sequence |
2 |
|
angiogenesis |
2 |
|
anti-viral therapy |
2 |
|
apoptosis/drug effects* |
2 |
|
arl4aa |
2 |
|
atra |
2 |
|
autologous regeneration |
2 |
|
beta catenin |
2 |
|
biological markers - blood |
2 |
|
bk virus - genetics |
2 |
|
bk virus-associated nephropathy |
2 |
|
blood donors |
2 |
|
bmp |
2 |
|
bone morphogenetic protein 4 |
2 |
|
bone morphogenetic proteins - physiology |
2 |
|
caspase-3 |
2 |
|
catheterization, central venous - adverse effects |
2 |
|
cell apoptosis |
2 |
|
cell differentiation |
2 |
|
cell migration |
2 |
|
cell proliferation/drug effects* |
2 |
|
chordin |
2 |
|
chromosome 17 |
2 |
|
chromosome 5 |
2 |
|
cystitis - virology |
2 |
|
decellularization |
2 |
|
definitive hematopoietic stem cells |
2 |
|
denileukin diftitox |
2 |
|
differentiation |
2 |
|
dose-response relationship, drug |
2 |
|
embryo development |
2 |
|
embryo, nonmammalian - embryology - metabolism |
2 |
|
equipment failure |
2 |
|
gene expression |
2 |
|
glycoproteins - physiology |
2 |
|
golgi complex |
2 |
|
graft vs host disease - blood - diagnosis - etiology |
2 |
|
graft vs host disease - blood - etiology |
2 |
|
graft vs host disease - prevention and control |
2 |
|
green fluorescent protein |
2 |
|
hematopoietic stem cell mobilization - methods - standards |
2 |
|
hemorrhage |
2 |
|
histone deacetylase inhibitors |
2 |
|
hodgkin disease - radiography |
2 |
|
iaps |
2 |
|
in vitro model |
2 |
|
intercellular signaling peptides and proteins - physiology |
2 |
|
leukemia-lymphoma, adult t-cell - complications - genetics - therapy |
2 |
|
lymphocyte count |
2 |
|
mesenchymal stem/stromal cell |
2 |
|
microarray |
2 |
|
mif |
2 |
|
mobilization |
2 |
|
morpholino |
2 |
|
multiple myeloma |
2 |
|
multiple myeloma - drug therapy - pathology |
2 |
|
multiple myeloma/pathology* |
2 |
|
myelodysplastic syndromes - complications - etiology - genetics |
2 |
|
neck - radiography |
2 |
|
niche |
2 |
|
nitric oxide |
2 |
|
nitric oxide - blood |
2 |
|
notch signaling |
2 |
|
nuclear pore complex proteins - genetics - metabolism - physiology |
2 |
|
osteogenic differentiation |
2 |
|
polyomavirus infections - etiology - virology |
2 |
|
ppar |
2 |
|
reduced intensity conditioning |
2 |
|
rosiglitazone |
2 |
|
screening |
2 |
|
subclavian vein - radiography |
2 |
|
t-cell lymphomas/leukemia |
2 |
|
t-lymphocytes, helper-inducer - cytology |
2 |
|
t-mds |
2 |
|
thiazolidinediones - pharmacology |
2 |
|
thiazolidinediones/pharmacology* |
2 |
|
transplantation conditioning - methods - standards |
2 |
|
transplantation, isogeneic - adverse effects |
2 |
|
tretinoin/pharmacology* |
2 |
|
tumors -- blood-vessels. |
2 |
|
tumors -- treatment. |
2 |
|
umbilical cord blood |
2 |
|
urine cytology |
2 |
|
zebra danio -- genetics. |
2 |
|
zebrafish proteins |
2 |
|
zebrafish proteins - genetics - metabolism - physiology |
2 |
|
adenosine 3',5'-cyclic monophosphate |
1 |
|
adenosine triphosphate - pharmacology |
1 |
|
adrenergic agonists - pharmacology |
1 |
|
adrenergic alpha-agonists - pharmacology |
1 |
|
adrenergic beta-agonists - pharmacology |
1 |
|
adrenergic beta-antagonists - pharmacology |
1 |
|
adrenoceptors |
1 |
|
aml subtype |
1 |
|
angelica sinensis |
1 |
|
angelica sinensis - chemistry |
1 |
|
angiogenesis inducing agents - pharmacology - therapeutic use - toxicity |
1 |
|
angiogenic proteins - genetics |
1 |
|
anions - metabolism |
1 |
|
anthranilic acids - pharmacology |
1 |
|
antigens, cd34 |
1 |
|
aorta - drug effects |
1 |
|
area compressibility |
1 |
|
bcl2 profiling |
1 |
|
biochemistry |
1 |
|
biological transport, active - drug effects - physiology |
1 |
|
biophysical properties |
1 |
|
blotting, western |
1 |
|
c/ebpα |
1 |
|
ca 2+ store |
1 |
|
calcitonin gene-related peptide - physiology |
1 |
|
calcium |
1 |
|
calcium - metabolism |
1 |
|
calcium - pharmacology |
1 |
|
calcium - physiology |
1 |
|
calcium-regulated chloride conductance |
1 |
|
calcium-transporting atpases - antagonists & inhibitors |
1 |
|
camp |
1 |
|
cancer patients |
1 |
|
cell culture |
1 |
|
cell culture techniques |
1 |
|
cell line |
1 |
|
cell mechanics |
1 |
|
cell movement - drug effects |
1 |
|
cell state |
1 |
|
cells, cultured |
1 |
|
cellular heterogeneity |
1 |
|
chemical synthesis |
1 |
|
chloride channels - drug effects - physiology |
1 |
|
chloride ion |
1 |
|
chloride secretion |
1 |
|
chlorides - metabolism |
1 |
|
chlorides - physiology |
1 |
|
cl- secretion |
1 |
|
coculture techniques |
1 |
|
crispr/cas9 |
1 |
|
culture techniques |
1 |
|
cyclic amp - analysis - pharmacology |
1 |
|
cyclic amp - metabolism |
1 |
|
cyclic amp - pharmacology |
1 |
|
cyclic amp - physiology |
1 |
|
cyclopamine hydrate c4116 (sigma) |
1 |
|
cystic fibrosis - physiopathology |
1 |
|
cystic fibrosis mouse |
1 |
|
cystic fibrosis mouse model |
1 |
|
cystic fibrosis transmembrane conductance regulator |
1 |
|
cytarabine phr1787 (sigma) |
1 |
|
deoxyribonucleases - metabolism |
1 |
|
diabetic foot - drug therapy |
1 |
|
diabetic foot ulcer |
1 |
|
drug resistance |
1 |
|
drugs, chinese herbal - pharmacology - therapeutic use - toxicity |
1 |
|
dymetil sulfoxide d8418 (sigma) |
1 |
|
egtazic acid - analogs & derivatives - pharmacology |
1 |
|
electric conductivity |
1 |
|
electrophysiology |
1 |
|
embryo, nonmammalian - blood supply - drug effects |
1 |
|
endothelial cells - cytology - drug effects - metabolism |
1 |
|
endothelial cells - drug effects - metabolism |
1 |
|
epididymis - chemistry - cytology - physiology |
1 |
|
epididymis - cytology - metabolism |
1 |
|
epididymis - drug effects - metabolism |
1 |
|
epididymis - metabolism |
1 |
|
epididymis - physiopathology |
1 |
|
epididymis - secretion |
1 |
|
epinephrine - metabolism |
1 |
|
epinephrine - pharmacology |
1 |
|
epithelia |
1 |
|
epithelial cells |
1 |
|
epithelium - chemistry - physiology |
1 |
|
epithelium - metabolism |
1 |
|
extracellular signal-regulated map kinases - metabolism |
1 |
|
fallopian tubes - physiology |
1 |
|
fetal blood |
1 |
|
fgf |
1 |
|
fluorescent antibody technique |
1 |
|
forskolin - pharmacology |
1 |
|
fura-2 acetoxymethyl ester |
1 |
|
g2 phase cell cycle checkpoints - drug effects |
1 |
|
gene expression regulation - drug effects |
1 |
|
genetic engineering - methods |
1 |
|
genome - genetics |
1 |
|
glasdegib pz0303 (sigma) |
1 |
|
hdac6 |
1 |
|
hedgehog |
1 |
|
hedgehog pathway |
1 |
|
hematopoietic cell |
1 |
|
hematopoietic stem cells - cytology - drug effects |
1 |
|
human biology |
1 |
|
huvec |
1 |
|
hypoosmotic swelling |
1 |
|
in-vitro drug screening |
1 |
|
indomethacin - pharmacology |
1 |
|
intrinsic property |
1 |
|
ion transport - drug effects - physiology |
1 |
|
ionomycin - pharmacology |
1 |
|
kinetics |
1 |
|
lethal dose 50 |
1 |
|
map kinase signaling system - drug effects |
1 |
|
map kinase signaling system - drug effects - genetics |
1 |
|
mapk |
1 |
|
mechanical response |
1 |
|
medicine |
1 |
|
membrane potentials - physiology |
1 |
|
membrane proteins - physiology |
1 |
|
mice, inbred c57bl |
1 |
|
microfluorimetry |
1 |
|
micromechanical property |
1 |
|
mirna profiling |
1 |
|
myeloid malignancy |
1 |
|
myelopoiesis |
1 |
|
myelopoiesis - drug effects |
1 |
|
nanomedicine |
1 |
|
neovascularization, physiologic - drug effects |
1 |
|
neovascularization, physiologic - drug effects - genetics |
1 |
|
next generation sequencing |
1 |
|
norepinephrine - pharmacology |
1 |
|
osmoregulation |
1 |
|
oviduct |
1 |
|
p38 mitogen-activated protein kinases - metabolism |
1 |
|
personalized medicine |
1 |
|
phenotype |
1 |
|
plant extracts - chemistry - pharmacology |
1 |
|
primary cilium |
1 |
|
prostaglandins - biosynthesis |
1 |
|
protein kinase |
1 |
|
proto-oncogene protein c-fli-1 - genetics |
1 |
|
radix astragali |
1 |
|
radix rehmanniae |
1 |
|
rat epididymis |
1 |
|
rats |
1 |
|
rats, sprague-dawley |
1 |
|
real-time polymerase chain reaction |
1 |
|
receptors, adrenergic, alpha - physiology |
1 |
|
receptors, adrenergic, beta - physiology |
1 |
|
reference values |
1 |
|
rna, messenger - genetics |
1 |
|
roscovitine r7772 (sigma) |
1 |
|
s phase - drug effects |
1 |
|
s phase cell cycle checkpoints - drug effects |
1 |
|
secretion |
1 |
|
seminal vesicles - physiopathology |
1 |
|
short-circuit current |
1 |
|
signal transduction - physiology |
1 |
|
single cells |
1 |
|
single-cell level |
1 |
|
sox genes |
1 |
|
staurosporine |
1 |
|
stretching force |
1 |
|
stromal cells - cytology - physiology |
1 |
|
talen |
1 |
|
terpenes - pharmacology |
1 |
|
thapsigargin |
1 |
|
theoretical approach |
1 |
|
tp53 signaling |
1 |
|
transient expression |
1 |
|
tubastatina hydrochloride sml0044 (sigma) |
1 |
|
umbilical veins - blood supply - cytology - drug effects - metabolism |
1 |
|
unique features |
1 |
|
vegf |
1 |
|
wound healing |
1 |
|
zebrafish - genetics |
1 |
|
zebrafish embryos |
1 |
|
α- and β-adrenergic agents |
1 |
|
β-catenin/wnt pathway |
1 |
